---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093278"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:18:18.584238+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports $658M cash, FDA breakthrough therapy for two candidates, net loss $57.2M in Q2

## Summary
- Cash, equivalents and securities $658.0M as of June 30, 2024; operating runway into 2027.
- Net loss $57.2M for Q2 2024; R&D expense $49.2M, G&A $16.0M.
- FDA breakthrough therapy designation for zidesamtinib (ROS1) and NVL-655 (ALK).
- Phase 2 enrollment ongoing for ALKOVE-1 (NVL-655) and ARROS-1 (zidesamtinib) with registrational intent; ESMO updates September 14.
- Initiated HEROEX-1 Phase 1a/1b trial for NVL-330 in HER2-altered NSCLC.

## SEC filing metadata
- accession: 0000950170-24-093278
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/0000950170-24-093278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/nuvl-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093278
- JSON: https://secwatch.observer/filing/0000950170-24-093278.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.